Floatz Rating
B57/100
Confidence
Indicative
Sponsor
University of Washington
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06039371CT.gov Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study | — | Recruiting | — | — | — |
NCT04704505CT.gov Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) | — | Recruiting | — | — | — |
NCT03516812CT.gov Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Testosterone Cipionate (this asset) | University of Washington | P2 | B · 57 |
| Docetaxel | Instituto do Cancer do Estado de São Paulo | P3 | BBB |
| Prednisone | Mayo Clinic | P3 | BB |
| Nilutamide | SWOG Cancer Research Network | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2 | BB |
| Degarelix | Canadian Cancer Trials Group | P3 | BB |
| Goserelin | CancerCare Manitoba | P3 | BB |
| Lidocaine | Bagcilar Training and Research Hospital | P4 | BB |
| Bicalutamide | OHSU Knight Cancer Institute | P3 | BB |
+42 more in the Prostate Adenocarcinoma cohort
Other indications for Testosterone Cipionate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Castration-Resistant Prostate Carcinoma | — | P2 | BB · 64 |
| Hypogonadism, Male | — | P4 | B · 62 |
| Prostate Cancer | — | P4 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Testosterone Cipionate in Prostate Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/testosterone-cipionate-prostate-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →